Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of antiplatelet effects of different dosages of aspirin in type 2 diabetic patients
2007-003186-40Phase 4Completed
- Sponsor
- Karolinska Institutet
- Start
- Jul 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of aspirin in type 2 diabetes mellitus (T2DM), microangiopathy and macroangiopathy (3 arms), sponsored by Karolinska Institutet. Primary endpoints: Arachidonic acid-induced platelet aggregation in whole blood, Arachidonic acid-induced platelet aggregation in platelet-rich plasma (PRP) and 1 more. Started Jul 2007; status: completed.
02
Drugs
aspirin
03
Conditions
type 2 diabetes mellitus (T2DM)microangiopathymacroangiopathy
Beyond the preview
Go deeper on 2007-003186-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003186-40.